Synthesis Institute's Psychedelic Practitioner Core Training
Training Program
Hybrid
Aug 19, 2023
8,997
USD
Online
13 Months
Awarded: Certificate of Completion
Description
Psychedelics are making significant progress on their path to legalization.
After decades of actively prohibiting these substances, which involved legal bans and misinformation about their mind-altering effects, resulting in limited scientific research, the tide is turning on government policy and public opinion.
Extensive research and professional literature have demonstrated the efficacy of psychedelics in promoting emotional, psychological, and spiritual growth. Groundbreaking milestones achieved through clinical trials conducted by prominent research institutions have validated the therapeutic effectiveness of these compounds, paving the way for a promising future in psychedelics.
In 2018, the U.S. FDA designated psilocybin as a "breakthrough therapy" for severe depression, surpassing existing treatments with substantial improvement.
Oregon took a pioneering step in 2020 by passing the Psilocybin Services Act, allowing the therapeutic administration of psilocybin starting in 2023. Colorado followed suit in 2022, legalizing psilocybin and allowing for the establishment of state-regulated consumption centers. This forward momentum is further evidenced by the growing shift in attitudes across multiple U.S. states, where decriminalization bills are being considered.
The global impact of this momentum is undeniable. Earlier this year, Australia approved the use of psilocybin in treating treatment-resistant depression. In the UK, the Parliament is actively engaged in discussions regarding the medical rescheduling of psilocybin. Simultaneously, the European Parliament has taken proactive measures by establishing the Action Group for Medical Use of Psychedelics, to position the European Union as a frontrunner in psychedelic regulation. These developments underscore the widespread recognition and the global opportunity that lies ahead in the field of psychedelics.
Yet, psychedelics are not a panacea. Alongside increased access, education on the rewards and risks associated with these substances is crucial.
The demand for highly skilled and professionally trained psychedelic facilitators is experiencing rapid growth.
Recognizing this need, the Synthesis Institute, drawing upon its pioneering history of offering legal psychedelic experiences to over 1,000 individuals, has developed the the Psychedelic Practitioner Core Training,
A 13-month educational journey designed for those eager to work in the psychedelic space, seeking a research-backed, wisdom-rich, somatically-informed, heart-centered approach to facilitation.
Join Healing Practitioners, Researchers, Coaches, Yoga Teachers, Nurses, Psychotherapists, Psychologists, Counselors, Chaplains, and Others Who Have Decided to Integrate Elements of Psychedelic Care Into Their Practice.
After decades of actively prohibiting these substances, which involved legal bans and misinformation about their mind-altering effects, resulting in limited scientific research, the tide is turning on government policy and public opinion.
Extensive research and professional literature have demonstrated the efficacy of psychedelics in promoting emotional, psychological, and spiritual growth. Groundbreaking milestones achieved through clinical trials conducted by prominent research institutions have validated the therapeutic effectiveness of these compounds, paving the way for a promising future in psychedelics.
In 2018, the U.S. FDA designated psilocybin as a "breakthrough therapy" for severe depression, surpassing existing treatments with substantial improvement.
Oregon took a pioneering step in 2020 by passing the Psilocybin Services Act, allowing the therapeutic administration of psilocybin starting in 2023. Colorado followed suit in 2022, legalizing psilocybin and allowing for the establishment of state-regulated consumption centers. This forward momentum is further evidenced by the growing shift in attitudes across multiple U.S. states, where decriminalization bills are being considered.
The global impact of this momentum is undeniable. Earlier this year, Australia approved the use of psilocybin in treating treatment-resistant depression. In the UK, the Parliament is actively engaged in discussions regarding the medical rescheduling of psilocybin. Simultaneously, the European Parliament has taken proactive measures by establishing the Action Group for Medical Use of Psychedelics, to position the European Union as a frontrunner in psychedelic regulation. These developments underscore the widespread recognition and the global opportunity that lies ahead in the field of psychedelics.
Yet, psychedelics are not a panacea. Alongside increased access, education on the rewards and risks associated with these substances is crucial.
The demand for highly skilled and professionally trained psychedelic facilitators is experiencing rapid growth.
Recognizing this need, the Synthesis Institute, drawing upon its pioneering history of offering legal psychedelic experiences to over 1,000 individuals, has developed the the Psychedelic Practitioner Core Training,
A 13-month educational journey designed for those eager to work in the psychedelic space, seeking a research-backed, wisdom-rich, somatically-informed, heart-centered approach to facilitation.
Join Healing Practitioners, Researchers, Coaches, Yoga Teachers, Nurses, Psychotherapists, Psychologists, Counselors, Chaplains, and Others Who Have Decided to Integrate Elements of Psychedelic Care Into Their Practice.
